Obicetrapib monotherapy/combination approved in Europe
NewAmsterdam Pharma received European Commission approval for Ubeslo and Evlarco, marking the first regulatory approval of its drug obicetrapib. The update also reported strategic clinical progress and strong cash reserves, signaling potential market expansion in lipid management.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed